The reimbursement by a national healthcare insurance system of a medicinal product for a use not covered by its marketing authorisation (off-label use) is not contrary to European Union law, the EU Court of Justice ruled on Wednesday 21 November (Case C-29/17).
Roche Italia has been granted a marketing authorisation for Avastin, a drug to treat certain cancers. This drug is also frequently prescribed for the treatment of the eye disease, age-related macular degeneration ARMD, despite the...